文献速递眼底病与葡萄膜炎

葡萄膜黑色素瘤敷贴放疗后预防性玻璃体腔注射贝伐珠单抗4年视力结局

Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

这项回顾性非随机干预队列研究在Wills眼科医院比较了敷贴放疗后预防性玻璃体腔注射贝伐珠单抗(摘除敷贴时及之后2年内每4个月1次、共6次)的1131眼与未注射的历史对照117眼。结果显示贝伐珠单抗组在24、36个月黄斑囊样水肿及24至48个月放射性黄斑病变、18个月放射性视乳头病变均更少,各随访点视力均更优,提示4年内视力结局更好。

要点

  • 预防性贝伐珠单抗组24、36个月OCT黄斑囊样水肿及24至48个月放射性黄斑病变更少。
  • 贝伐珠单抗组12至48个月各时点视力均优于历史对照,48个月中位logMAR 0.54对2.00。
  • 结果为回顾性非随机对照,随访时长两组不一致,需谨慎解读。

核心结论

  • 敷贴放疗的葡萄膜黑色素瘤患者预防性玻璃体腔注射贝伐珠单抗,与历史对照相比4年内视力结局更好。

研究设计与样本

  • 回顾性、非随机、干预性队列研究,地点为美国费城Wills眼科医院。
  • 贝伐珠单抗组为2008至2018年1131眼接受放疗的葡萄膜黑色素瘤,历史对照组为2007至2009年117眼。
  • 预防性贝伐珠单抗于摘除敷贴时给予,并在此后2年内每4个月注射1次、共6次。

主要发现

  • 两组人口学特征、临床特征及放疗参数未见差异,平均随访分别为40个月与56个月(均差-18;95%CI,-24至-13;P<.001)。
  • 贝伐珠单抗组24个月OCT黄斑囊样水肿28%对37%(HR 1.5;95%CI 1.1-2.2;P=.02),36个月44%对54%(HR 1.5;95%CI 1.1-2.1;P=.01)。
  • 放射性黄斑病变24个月27%对36%(P=.03)、36个月44%对55%(P=.01)、48个月61%对66%(P=.03),放射性视乳头病变18个月6%对12%(HR 2.0;95%CI 1.1-3.9;P=.04)。
  • 中位logMAR视力(Snellen等效)12个月0.30(20/40)对0.48(20/60),24个月0.40(20/50)对0.70(20/100),36个月0.48(20/60)对1.00(20/200),48个月0.54(20/70)对2.00(数指)。

关键数值与推荐

  • 预防性方案为摘除敷贴时注射及之后2年内每4个月1次、共6次玻璃体腔贝伐珠单抗。
  • 患者中位年龄61岁,1248例中1195例为白人(96%)、632例为女性(51%)。
  • 中位肿瘤厚度4.0 mm,距中心凹中位距离3.0 mm。

临床怎么用

  • 对接受敷贴放疗的葡萄膜黑色素瘤患者,可考虑预防性玻璃体腔贝伐珠单抗以减轻放射性视网膜病变并保留视力。
  • 该方案为每4个月1次、持续2年,需结合患者随访依从性与注射风险个体化决策。

局限性

  • 为回顾性、非随机研究,对照为历史人群,存在选择偏倚可能。
  • 两组平均随访时长不同(40个月对56个月),可能影响结局比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Radiation retinopathy following plaque radiotherapy for uveal melanoma can lead to vision loss that might be avoided with prophylactic anti-vascular endothelial growth factor treatment. OBJECTIVE: To determine visual outcome following prophylactic intravitreal bevacizumab in patients with plaque-irradiated uveal melanoma. DESIGN, SETTING, AND PARTICIPANTS: Retrospective, nonrandomized, interventional cohort study at Wills Eye Hospital, Philadelphia, Pennsylvania. Prophylactic bevacizumab was administered between 2008 and 2018 to 1131 eyes with irradiated uveal melanoma (bevacizumab group) and compared with 117 eyes with irradiated uveal melanoma between 2007 and 2009 (no bevacizumab [historical control] group). INTERVENTIONS: Prophylactic intravitreal bevacizumab was provided at the time of plaque removal as well as 6 subsequent injections at 4-month intervals over 2 years. MAIN OUTCOMES AND MEASURES: Visual acuity. RESULTS: The median patient age was 61 years, 1195 of 1248 patients were white (96%), and 632 of 1248 were women (51%). The median tumor thickness was 4.0 mm, and median distance to foveola was 3.0 mm. A difference was not identified (bevacizumab vs control group) in demographic features, clinical features, or radiation parameters. The mean follow-up was 40 months vs 56 months (mean difference, -18; 95% CI, -24 to -13; P < .001). By survival analysis, the bevacizumab group demonstrated less optical coherence tomography evidence of cystoid macular edema at 24 months (28% vs 37%; hazard ratio [HR], 1.5; 95% CI, 1.1-2.2; P = .02) and 36 months (44% vs 54%; HR, 1.5; 95% CI, 1.1-2.1; P = .01), less clinical evidence of radiation maculopathy at 24 months (27% vs 36%; HR, 1.5; 95% CI, 1.0-2.2; P = .03), 36 months (44% vs 55%; HR, 1.50; 95% CI, 1.1-2.0; P = .01), and 48 months (61% vs 66%; HR, 1.4; 95% CI, 1.0-1.9; P = .03), and less clinical evidence of radiation papillopathy at 18 months (6% vs 12%; HR, 2.0; 95% CI, 1.1-3.9; P = .04). Nonparametric analysis documented better visual acuity outcomes in the bevacizumab group at all points, including 12 months (median logMAR visual acuity [Snellen equivalent]: 0.30 [20/40] vs 0.48 [20/60]; mean difference, -0.28; 95% CI, -0.48 to -0.07; P = .02), 24 months (0.40 [20/50] vs 0.70 [20/100]; mean difference, -0.52; 95% CI, -0.75 to -0.29; P < .001), 36 months (0.48 [20/60] vs 1.00 [20/200]; mean difference, -0.49; 95% CI, -0.76 to -0.21; P = .003), and 48 months (0.54 [20/70] vs 2.00 [counting fingers]; mean difference, -0.71; 95% CI, -1.03 to -0.38; P < .001). CONCLUSIONS AND RELEVANCE: These findings from a retrospective cohort of plaque radiotherapy and prophylactic intravitreal bevacizumab in patients with uveal melanoma suggest better visual outcomes when compared with nonrandomized historical control individuals through 4 years.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Shields CL, Dalvin LA, Chang M, et al. Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals. JAMA Ophthalmol. 2020. PMID: 31830238. doi:10.1001/jamaophthalmol.2019.5132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。